Neuronetics (NASDAQ:STIM) Releases Earnings Results, Misses Expectations By $0.07 EPS

Neuronetics (NASDAQ:STIM) released its quarterly earnings results on Tuesday. The company reported ($0.33) EPS for the quarter, missing the consensus estimate of ($0.26) by ($0.07), Zacks reports. Neuronetics had a negative net margin of 50.09% and a negative return on equity of 141.24%. Neuronetics updated its FY 2025 guidance to EPS and its Q1 2025 guidance to EPS.

Neuronetics Stock Performance

Shares of NASDAQ:STIM opened at $4.26 on Tuesday. The company has a quick ratio of 2.87, a current ratio of 3.16 and a debt-to-equity ratio of 4.90. Neuronetics has a 12-month low of $0.52 and a 12-month high of $5.07. The company’s 50 day moving average price is $2.85 and its two-hundred day moving average price is $1.62. The firm has a market cap of $129.28 million, a PE ratio of -3.46 and a beta of 2.17.

Insider Activity at Neuronetics

In related news, CFO Stephen Furlong sold 10,845 shares of the business’s stock in a transaction on Wednesday, February 12th. The stock was sold at an average price of $3.83, for a total transaction of $41,536.35. Following the sale, the chief financial officer now owns 471,727 shares in the company, valued at $1,806,714.41. The trade was a 2.25 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CEO Keith J. Sullivan sold 40,992 shares of Neuronetics stock in a transaction on Monday, February 10th. The stock was sold at an average price of $3.28, for a total transaction of $134,453.76. Following the transaction, the chief executive officer now owns 1,283,362 shares in the company, valued at approximately $4,209,427.36. This trade represents a 3.10 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 98,125 shares of company stock worth $348,876. Company insiders own 9.80% of the company’s stock.

Neuronetics Company Profile

Neuronetics, Inc, a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder.